Search

t-Butylhydroquinone

2,3-Dimercapto-1-propanesulfonic acid

TBC-3711

TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.

Mianserin

Mianserin was previously available internationally, however in most markets it has been phased out in favour of [mirtazapine].

ISIS 325568

It was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping control type 2 diabetes. … ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR).

XR5944

XR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.

trans NV-04

trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.

3,4-Methylenedioxy-N-isopropylamphetamine

MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). … MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF").

Tirilazad

Tirilazad has been used in trials studying the treatment of Spinal Cord Injury.

ALTU-135

This consistent and pure enzyme combination is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals. … ALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase